XML 24 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Segment information (Tables)
3 Months Ended
Mar. 31, 2020
Segment information  
Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2019

in EUR k

    

Pharmaceutical

    

Diagnostics

    

Corporate

    

Total

Total Revenues from contracts with external customers

 

4,130

 

6,585

 

 —

 

10,715

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

2,944

 

11

 

(3,820)

 

(865)

 

 

 

 

 

 

 

 

 

Capital Expenditures

 

 

 

 

 

 

 

 

Additions to property, plant and equipment and right-of-use assets

 

 7

 

20

 

414

 

441

Additions to intangible assets

 

768

 

 —

 

345

 

1,113

 

 

 

 

 

 

 

 

 

Other segment information

 

 

 

 

 

 

 

 

Depreciation and amortization

 

256

 

524

 

617

 

1,397

Research and development expenses

 

 —

 

 —

 

1,701

 

1,701

 

 

 

 

 

 

 

 

 

 

 

 

Three months ended March 31, 2020

in EUR k

    

Pharmaceutical

    

Diagnostics

    

Corporate

    

Total

Total Revenues from contracts with external customers

 

4,550

 

7,555

 

 —

 

12,105

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

2,608

 

87

 

(7,712)

 

(5,017)

 

 

 

 

 

 

 

 

 

Capital Expenditures

 

 

 

 

 

 

 

 

Additions to property, plant and equipment and right-of-use assets

 

 —

 

817

 

587

 

1,404

Additions to intangible assets

 

1,002

 

 —

 

189

 

1,191

 

 

 

 

 

 

 

 

 

Other segment information

 

 

 

 

 

 

 

 

Depreciation and amortization

 

564

 

544

 

976

 

2,084

Research and development expenses

 

 —

 

 —

 

2,691

 

2,691

 


 

 

 

 

 

For the three months ended March 31

    

2019

    

2020

Reported segment Adjusted EBITDA

 

2,955

 

2,695

Corporate expenses

 

(3,820)

 

(7,712)

 

 

(865)

 

(5,017)

Share-based payment expenses

 

(2,633)

 

(1,057)

Depreciation and amortization

 

(1,397)

 

(2,084)

Operating loss

 

(4,895)

 

(8,158)

Financial costs, net

 

(212)

 

(449)

Income tax expenses

 

(174)

 

(129)

Loss for the three months ended March 31

 

(5,281)

 

(8,736)